Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Daily Temozolomide for Low-Grade Glioma
NCT00165360Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2001
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in glioma, sponsored by Dana-Farber Cancer Institute. Started Sep 2001; status: completed.
02
Drugs
temozolomide
03
Conditions
glioma
Beyond the preview
Go deeper on NCT00165360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165360.